Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Palatin Technologies Inc PTN

Healthcare Biotechnology

Palatin Technologies, Inc. is a biopharmaceutical company. The Company is engaged in developing medicines based on molecules that modulate the activity of the melanocortin receptor system. The Company’s product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical needs and commercial potential. Its new product development activities focus... see more

Add To Watchlist

Recent & Breaking News (NYSEAM:PTN)

Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2019 Results; Teleconference and Webcast to be held on May 9, 2019

PR Newswire May 9, 2019

Palatin Technologies, Inc. to Report Third Quarter Fiscal Year 2019 Results; Teleconference and Webcast to be held on May 9, 2019

PR Newswire May 3, 2019

Palatin Technologies Announces Positive Top Line Results of Oral Clinical Study of PL-8177 for Ulcerative Colitis and Other Inflammatory Bowel Diseases

PR Newswire April 4, 2019

Palatin Technologies, Inc. Reports Second Fiscal Quarter 2019 Results and Provides Corporate Update

PR Newswire February 12, 2019

Palatin Technologies, Inc. to Report Second Quarter Fiscal Year 2019 Results; Teleconference and Webcast to be held on February 12, 2019

PR Newswire February 6, 2019

Palatin Technologies, Inc. Reports First Fiscal Quarter 2019 Results and Provides Corporate Update

PR Newswire November 13, 2018

Palatin Technologies, Inc. Announces First-in-Human Study Results of Subcutaneous Administration of PL-8177, An Investigational Melanocortin Receptor 1 Agonist

PR Newswire November 8, 2018

Palatin Technologies, Inc. to Report First Quarter Fiscal Year 2019 Results; Teleconference and Webcast to be held on November 13, 2018

PR Newswire November 7, 2018

Immunotherapy Market Value Grows as the Treatments Gains Widespread Importance

PR Newswire September 13, 2018

Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year 2018 Results

PR Newswire September 13, 2018

Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year End 2018 Results; Teleconference and Webcast to be held on September 13, 2018

PR Newswire September 7, 2018

Global Biotechnology Market Grows as Demand for Immunotherapy Cancer Treatment Increases

PR Newswire September 7, 2018

Palatin Technologies Added to Russell 3000® Index

PR Newswire June 25, 2018

Palatin Technologies Announces FDA Acceptance for Review of Bremelanotide NDA

PR Newswire June 4, 2018

Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2018 Results; Teleconference and Webcast to be held on May 15, 2018

PR Newswire May 15, 2018

Palatin Technologies, Inc. to Report Third Quarter Fiscal Year 2018 Results; Teleconference and Webcast to be held on May 15, 2018

PR Newswire May 10, 2018

Palatin Technologies Presents Positive Preclinical MC1 Receptor Agonist Data at TIDES: Oligonucleotide and Peptide Therapeutics 2018 Meeting in Boston, Massachusetts

PR Newswire May 9, 2018

Palatin Technologies Presents Preclinical Oral Formulation Data on PL-8177, An Investigational Melanocortin Receptor 1 Agonist for Inflammatory Bowel Diseases

PR Newswire April 3, 2018

Palatin Technologies Announces Submission of Bremelanotide NDA to FDA for Treatment of Hypoactive Sexual Desire Disorder (HSDD) in Premenopausal Women

PR Newswire March 26, 2018

Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2018 Results; Teleconference and Webcast to be held on February 12, 2018

PR Newswire February 12, 2018